Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNONCOVID-20 in advanced or metastatic cancer patients with COVID-19
2020-001373-70Phase 2Terminated
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ezurpimtrostat, nivolumab and tocilizumab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Centre Léon Bérard. Primary endpoint: 28-day survival rate. Started Mar 2020; status: terminated.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001373-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001373-70.